US research roundup: Cabot, Ionis Pharmaceuticals, Tesla
CBT•Analysts cut target prices for Cabot, Ionis Pharmaceuticals and Tesla. Ionis received five cuts, with targets ranging from $54 to $72; Jefferies cut Tesla’s target to $375 from $400 and JPMorgan cut Cabot’s to $68 from $78.
1. Analyst target changes
Analysts revised ratings and price targets on numerous U.S.-listed companies. For Cabot, JPMorgan lowered its target to $68 from $78. Jefferies cut its Tesla target to $375 from $400.
2. Ionis targets lowered
Five firms cut their Ionis Pharmaceuticals targets: Canaccord Genuity to $72 from $85, Jefferies to $61 from $80, Needham to $54 from $86, Raymond James to $54 from $79, and RBC to $60 from $85.
